The current research hotspots related to melanoma immunotherapy are as follows: 1) the optimal dosing schedule and patient selection for dual-ICB; 2) comprehensive and robust predictive biomarkers/models; 3) PD-L1 in combination with targeted therapy; 4) management of irAEs; 5) neoadjuvant and adjuvant immunotherapy; 6) overcoming inherent and acquired drug resistance; and 7) next generation immunotherapy. This evidence concerns the gene CD274 and melanoma.